Clinical Trial Update: SAD of IVT PYC-001 in OPA1 Mutation-Associated Autosomal Dominant Optic Atrophy (Sundew) [Phase 1]

View source ↗

Summary

Phase 1 single-ascending-dose trial of IVT PYC-001 in OPA1 mutation-associated autosomal dominant optic atrophy; the trial is currently active and not recruitin…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Autosomal Dominant Optic Atrophy

Drugs mentioned

• IVT PYC-001 (PYC-001)

Snippet

Sponsor: PYC Therapeutics | Conditions: OPA1 Gene Mutation, Autosomal Dominant Optic Atrophy | Phase 1 | Status: ACTIVE_NOT_RECRUITING